Adare Pharma Solutions
1200 Lenox Drive, Suite 100
Lawrenceville, NJ 08648
T: 609-450-1312


Adare Pharma Solutions is a global technology-driven CDMO providing turnkey product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical, Animal Health, and OTC markets. Adare’s specialized technology platforms provide taste masking, ODTs, and customized drug-release solutions. With a proven history in drug delivery, Adare has developed and manufactured more than 40 products sold by customers in more than 100 countries globally.



Adare Pharma Solutions has four sites located in the US and Europe with over 600 employees worldwide. We have the expertise to take your project from formulation development through commercial-scale manufacturing. Our sites are compliant with cGMP criteria and approved to handle controlled substances and maintain excellent environmental credentials. Our in-house regulatory and quality teams have a proven global track record with the FDA, AIFA in Italy, EMA in Europe, and ANVISA for Brazil.


Adare has recently launched a new patient-centric dosage solution, the ParvuletTM Technology. The ParvuletTM Technology enables a solid powder or tablet to convert to a semi-solid in the presence of water within 30 seconds. The final dosage is easily administered as a soft food like texture, which is ideal for pediatric and geriatric populations (including those with dysphagia).


Microcaps® Taste Masking Technology achieves uniform and efficient coating of drug particles by a combination of coacervation (phase separation) and spray coating to build polymeric membranes of varying porosity and thickness. The completely encapsulated particle allows for a pleasant mouthfeel without an aftertaste. The Microcaps technology can be applied to multiple dosage forms and immediate- and modified-release profiles.

AdvaTab® Orally Disintegrating Tablets (ODTs) incorporates coated or uncoated drug particles that are uniformly dispersed in a low-moisture, rapidly disintegrating matrix.Each ODT is formulated to achieve an acceptable taste and desired release profile. AdvaTab® technology is ideal for patients who have difficulty swallowing, pediatric, geriatric, and dysphagic patients.This technology can be combined with Microcaps® and Diffucaps® to create IR or controlled-release ODTs.

Diffucaps® Customized Release Technology
has the flexibility to incorporate functional, release-controlling polymers or protective coatings onto drug-layered cores, granules, or crystals. This allows for easy adjustment of both dosage strength and dissolution profile to achieve the desired in vivo pharmacokinetic profile. Beads can have different release profiles, different active ingredients, or both — all in one product.

MMTSTM Multi Mini Tablet System Customized Release Technology combines the simplicity of a tablet formulation with the flexibility of multiparticulate dosage forms with high drug-loading capability. Adare has developed Ultra Microtablets — a smaller standard of tablets targeting diameters in the range of 1.2 mm to even 1.0 mm. The small size facilitates the development of products that can offer multiple drugs or varying release profiles within a single capsule.

The DIFFUTAB® Technology is an effective solution for targeted drug delivery through customized and sustained release. The technology assists the development of high-dosage and sustained-release products for once-daily administration. A matrix tablet is coated with functional polymers, followed by a blend of hydrophilic and hydrophobic polymers. Layered erosion and diffusion of the drug matrix tablet result in a controllable release.

ORBEXA™, a solvent-based granulation and extrusion technology is applicable for capsules and single-unit sachets. The granulation spheronization and extrusion techniques produce beads of controlled size and density. The beads are coated with functional polymers to provide high drug concentrations and additional rates of control.  The technology’s high-speed process can accommodate sensitive molecules like proteins and are suitable for high drug loading.

Precision Particle Fabrication® Technology produces uniform microspheres and microcapsules with narrow size distribution and precise control over particle structure. The platform technology is flexible and customizable to accommodate a broad range of active ingredients, including small molecules, peptides, and proteins. The technology uses two physical processes simultaneously to create uniform droplets piezoelectric vibration and a co-flowing non-solvent “carrier” stream. For any given mass flow rate, droplet size can be reduced simply by increasing the frequency of vibration. The technology includes three platforms: Optimμm®, for oral delivery; StratμmTM, for injectable delivery; and Unisun®, for otic delivery.

The Optimµm® Technology creates microspheres with high drug loading suitable for taste masking, enteric coatings, and extended-release oral applications. The technology is capable of producing single- or double-layer particles in a one manufacturing step, lending to cost-effective creation of palatable dosage forms, which mimic traditional tablets, pills, and capsules. The Optimµm® technology allows for unprecedented control in release rate and dosage form properties. This technology is ideal for oral small molecules, nutraceuticals, agricultural applications, flavorings, and heat-stable molecules.

The Stratµm™ Technology, for injectable delivery, allows for precise control of particle size and composition, enabling predictable injectable performance, which is critical for self-administration, extended-release, and modified-release applications with a narrow therapeutic index. Unlike other encapsulation techniques, Stratμm® is capable of producing single- or double-layer particles in a one manufacturing step, lending to creation of next-generation “pulsatile” release formulations or extended-release formulations. This technology is ideal for injectable small molecules, proteins, peptides, vaccines, and heat-labile molecules and requires lyophilization.

The Unisun® Technology combines the use of encapsulated or free drug, along with a fast-film forming agent, which allows for low-cost, long-acting intratympanic delivery of a therapeutic. The technology allows for less-frequent administrations than current therapies and is capable of sustaining drug levels in the inner ear cochlea for weeks. The technology can be used inject and set up highly concentrated depots of a drug and is ideal for small molecules, proteins, peptides, and vaccines.